189 related articles for article (PubMed ID: 25501128)
21. Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Bex A; de Gast G; Haanen JB; Boven E
Clin Cancer Res; 2008 Apr; 14(8):2431-6. PubMed ID: 18413834
[TBL] [Abstract][Full Text] [Related]
22. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
[TBL] [Abstract][Full Text] [Related]
23. Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
Bousquet G; Varna M; Ferreira I; Wang L; Mongiat-Artus P; Leboeuf C; de Bazelaire C; Faivre S; Bertheau P; Raymond E; Germain S; Janin A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1183-93. PubMed ID: 24061866
[TBL] [Abstract][Full Text] [Related]
24. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
25. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy.
Lim ZD; Mahajan A; Weinberg J; Tannir NM
Am J Clin Oncol; 2013 Jun; 36(3):258-60. PubMed ID: 22441343
[TBL] [Abstract][Full Text] [Related]
26. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
Mikami S; Mizuno R; Kosaka T; Saya H; Oya M; Okada Y
Int J Cancer; 2015 Apr; 136(7):1504-14. PubMed ID: 25123505
[TBL] [Abstract][Full Text] [Related]
27. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
28. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib.
Choueiri TK; Mosquera JM; Hirsch MS
Clin Genitourin Cancer; 2009 Oct; 7(3):E93-4. PubMed ID: 19815489
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
Park S; Lee J; Park SH; Park JO; Kang WK; Park YS; Cho JH; Lim HY
Chemotherapy; 2010; 56(6):485-91. PubMed ID: 21099221
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM
FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
33. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
34. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
[TBL] [Abstract][Full Text] [Related]
35. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Heng DY; Rini BI; Garcia J; Wood L; Bukowski RM
Clin Genitourin Cancer; 2007 Dec; 5(7):446-51. PubMed ID: 18272027
[TBL] [Abstract][Full Text] [Related]
36. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
37. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
Dong Y; Manley BJ; Becerra MF; Redzematovic A; Casuscelli J; Tennenbaum DM; Reznik E; Han S; Benfante N; Chen YB; Arcila ME; Aras O; Voss MH; Feldman DR; Motzer RJ; Fabbri N; Healey JH; Boland PJ; Chawla M; Durack JC; Lee CH; Coleman JA; Russo P; Hakimi AA; Cheng EH; Hsieh JJ
Eur Urol Focus; 2017 Dec; 3(6):590-598. PubMed ID: 28753786
[TBL] [Abstract][Full Text] [Related]
38. Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Gore ME; Hariharan S; Porta C; Bracarda S; Hawkins R; Bjarnason GA; Oudard S; Lee SH; Carteni G; Nieto A; Yuan J; Szczylik C
Cancer; 2011 Feb; 117(3):501-9. PubMed ID: 20862748
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
40. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
